Clinical Investigation of Two Different Wound Dressings

NCT ID: NCT02904200

Last Updated: 2021-04-01

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

NA

Total Enrollment

2 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-10-31

Study Completion Date

2017-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The primary objective of this investigation is to evaluate changes on Peri-Wound skin from baseline to termination when using two different wound dressings

The secondary objectives are to evaluate pain before, during, and after dressing removal from baseline to termination

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

A prospective randomized clinical investigation will be conducted at two sites in Sweden.

Male or female, 18 years or older with following wound types:

* traumatic, surgical or dehisced wounds,
* venous leg ulcer or pressure ulcer will be included into the clinical investigation.

32 evaluated subjects (i:e 16 subjects per arm) will be followed during maximum three weeks. The treatment arm (either silicon adhesive dressing or acrylic adhesive dressing). Patients will be randomized using optimal allocation (minimization) balancing for the following baseline variables type of skin (normal/dry/flaky/oily/moist) and age. Eligible patients will be randomized to receive either silicon adhesive dressing or acrylic adhesive dressing in a ratio of 1:1 provided.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Wounds and Injuries

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Silicon adhesive dressing

Sterile soft silicon adhesive dressing

Group Type EXPERIMENTAL

Silicon adhesive dressing

Intervention Type DEVICE

Sterile soft silicon adhesive dressing

Acrylic adhesive dressing

Sterile acrylic adhesive dressing

Group Type ACTIVE_COMPARATOR

Acrylic adhesive dressing

Intervention Type DEVICE

Sterile acrylic adhesive dressing

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Silicon adhesive dressing

Sterile soft silicon adhesive dressing

Intervention Type DEVICE

Acrylic adhesive dressing

Sterile acrylic adhesive dressing

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Traumatic, surgical or dehisced wounds, Venous Leg Ulcer, Diabetic Foot Ulcer or Pressure Ulcer indicated for treatment with NPWT therapy
2. In case of multiple wounds the target wound must be ≥10 cm distant from other wounds. Selection of the target wound is according to the investigator's preference.
3. Peri-wound skin assessable and 5 cm of peri-wound skin present around the wound
4. Male or female, 18 years of age and above
5. Signed Informed Consent

Exclusion Criteria

1. Dressing sizes does not fit the target wound
2. Unexplored blind tunnels or non-enteric fistula
3. Untreated osteomyelitis
4. Malignant wounds
5. Subjects treated with systemic immunosuppressive or glucocorticosteroids, except subjects taking occasional doses or doses less than 10mg prednisolon/day or equivalent.
6. Wounds with necrotic tissue or eschar (if not adequately debrided)
7. Significantly bleeding wounds, as judged by the investigator
8. Subject not suitable for the investigation according to the investigator's judgment
9. Subject included in other ongoing clinical investigation which could interfere with this investigation, as judged by the investigator
10. Known allergy/hypersensitivity to any of the components included into the investigation.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Molnlycke Health Care AB

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Marianne Bergstrom

Role: PRINCIPAL_INVESTIGATOR

Sundsvalls Sjukhus

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Sundsvalls sjukhus

Sundsvall, , Sweden

Site Status

Norrlands Universitetssjukhus

Umeå, , Sweden

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Sweden

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Study Protocol and Statistical Analysis Plan

View Document

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Avance 02

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.